You are here: News REGISTRATION ON PRIORITY BASIS.

REGISTRATION ON PRIORITY BASIS.

REGISTRATION ON PRIORITY BASIS


NOTICE

Since the number of registered suppliers are limited, NMRA has decided to entertain

new applications for following products and priority evaluation will be granted for such.


1.Antiretroviral medicines of already approved molecules.

2.Lithium Carbonate Tablets of 250 mg & 400 mg.

3.Methotrexate Tablets of 2.5 mg.

4.Oral Morphine Tablets of 10 mg, 15 mg & 30 mg / Slow

release Tablets of 15 mg & 30 mg / Syrup.

 

 

 

Dr. Kamal Jayasinghe,

Chief Executive Officer,

NMRA.